KALV — Kalvista Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $621.80m
- $411.40m
- 25
- 17
- 80
- 35
Annual cashflow statement for Kalvista Pharmaceuticals, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -29.1 | -46.2 | -82.3 | -92.9 | -127 |
| Depreciation | |||||
| Non-Cash Items | 4.43 | 7.19 | 16 | 9.52 | 21.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -20.6 | 8.35 | -12.3 | 7.41 | 15.2 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -44.8 | -30.2 | -78.1 | -75.3 | -89.2 |
| Capital Expenditures | -0.22 | -0.082 | -0.931 | -1.2 | -0.443 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | 17 | -148 | 58.8 | 42.6 | -84.3 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 16.8 | -148 | 57.9 | 41.4 | -84.7 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 11.6 | 212 | 1.58 | 58.1 | 151 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -16.2 | 34.8 | -19.9 | 25.5 | -24.4 |